Etoricoxib, a highly selective cyclooxygenase-2 inhibitor (CSI), appears to be a more effective treatment for rheumatoid arthritis (RA) than naproxen, according to a report published in the August issue of the Journal of Rheumatology.
Etoricoxib, produced by Merck and Co., Inc. under the trade name Arcoxia, was submitted to the US Food and Drug Administration for approval last year. But Merck withdrew the application in March 2002 so that it could add data supporting the drug’s use in ankylosing spondylitis. Since then, the FDA has requested additional cardiovascular safety data in comparison to drugs other than naproxen.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!